N/A N=31 Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
Hemodialysis · Kidney Failure, Chronic
Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=55 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients
Hyperphosphatemia
Primary: Phosphorus Levels — 5.3; 5.6; 5.4; 6 mg/dL
N/A N=126 Blood Pressure in Dialysis Patients
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
N/A N=86 Recovery Time and Affecting Factors in Hemodialysis Patients
Dialysis; Complications · Life Quality
Primary: Post-dialysis Recovery Time — 278.02 minutes
N/A N=8 Continuous Cardiac Arrhythmia Monitoring in Hemodialysis Patients
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
N/A N=16 Expanded Hemodialysis Versus Online Hemodiafiltration
Dialysis Related Complication · Dialysis Hypotension · Hemodialysis-Induced Symptom
Primary: Medium Molecule Clearance — 53; 59.5 ml/min — p=0.4534
N/A N=6 Intradialytic Drug Removal by Short-daily Hemodialysis
End Stage Renal Disease · Infection
Primary: Intradialytic Clearance of Levofloxacin, Gentamicin and Vancomycin in Patients Receiving Short-daily Hemodialysis — 7.2; 7.6 ml/min
N/A N=36 Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD
End-Stage Renal Disease
Primary: Primary Safety Endpoint — 16.1; 11.6 Adverse Events per 100 Treatments
N/A N=172 Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
End Stage Renal Disease
Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio
Phase 1 N=119 HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
End Stage Renal Disease on Hemodialysis (Diagnosis)
Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…
Phase 4 N=8 Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
N/A N=19 Pilot Study of Nutrition in Maintenance Hemodialysis Patients
End-Stage Renal Disease · Meals · Hemodialysis
Primary: Hypotensive Event Frequency — 18; 13 events
N/A N=240 POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study
Hyperkalemia
Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants
N/A N=1,431 Enhancing the Cardiovascular Safety of Hemodialysis Care (Dialysafe)
Kidney Failure · End Stage Renal Disease · Hypotension
Primary: Dialysis Session Stability — 0.202; 0.199; 0.172; 0.182 Proportion of sessions
N/A N=16 Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™
Chronic Kidney Diseases · Patient Requiring Heparin Free Dialysis Treatments
Primary: The Primary Endpoint is the Number and Percent (%) of Successful Heparin-free HD Sessions for Each Subject in Each Circuit. — 2.4; 2.9 number of successful HD sessions
Phase 2 N=52 Mannitol - Potential Role in Hemodialysis Initiation for Reduction of Intra-dialytic Hypotension
Intra-dialytic Hypotension
Primary: Efficacy of Mannitol Administration in Reducing the Frequency of Intra-dialytic Hypotension (Decline in Systolic Blood Pressure) During the First Three Hemodialysis…
Phase 4 N=309 20070360 Incident Dialysis
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
Phase 2 N=12 Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease
Hypertension · End Stage Renal Disease
Primary: Change in Mean Interdialytic 44-hour Ambulatory Systolic Blood Pressure Over a 2 Week Follow-up Period — -1.5; -3.7; -0.4 mm Hg
N/A N=11 A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients
End Stage Renal Disease (ESRD)
Primary: Clearance and Solute Removal Characteristics of Dialyzers — 354.1; 340.4; 361.8; 271.8 milliliters per minute (ml/min) — p=<0.001
N/A N=4 Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
Phase 4 N=46 PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis
Hepatitis Viruses
Primary: Number of Participants With Sustained Virologic Response (SVR12) — 46 Participants
Phase 2 N=7 Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients
End Stage Renal Disease
Primary: Mean Maximum Concentration (Cmax) of Ertapenem in Hemodialysis Patients — 663.1 mcg/ml
Phase 4 N=352 Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients
Hepatitis B Vaccine
Primary: Anti-HBs Seroconversion Rate at Month 7 — 118; 132 Participants
Phase 4 N=4 Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
Hepatitis C · Hemodialysis · Nosocomial Infection
Primary: SVR - Sustained Virologic Response — 3; 0; 1; 0 Participants
N/A N=34 Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
Phase 4 N=377 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Sustained Virologic Response (SVR)Rate — 130; 72 participants — p=< 0.001
N/A N=179 Intervention to Reduce Dietary Sodium in Hemodialysis
Renal Dialysis
Primary: Time Specific Interdialytic Weight Gain (Baseline) — 1.2; 1.2 kg/day
N/A N=102 Shared Decision Making in Dialysis
End Stage Renal Disease · Chronic Kidney Diseases
Primary: Mean Feasibility of Intervention Measure — 16.4; 16.1; 19.0 score on a scale
N/A N=32 Mechanisms and Phenotypes of Hypertension in Patients in Chronic Hemodialysis
Arterial Hypertension · Hemodialysis
Primary: Cardiac Output — 3.9; 4.10; 4.6 L/min
N/A N=16 Treatment Modification to Reduce Symptom Burden in Hemodialysis
End Stage Renal Disease
Primary: Number of Participants Recruited, Consented, Randomized and Completed — 51; 16; 16; 16 Participants